Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer

NCT05722795 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT05722795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05722795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer
Lead sponsor
Vastra Gotaland Region
Phase
Not applicable
Overall status
Recruiting
Start date
June 1, 2023
Completion date
December 28, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer